Graft-versus-host disease acute

Imaging modalities are not utilized to detect rejection and graft-versus-host disease. Acute rejection is diagnosed by endoscopy combined with mucosal biopsies from donor stomach, duodenum or distal ileum via the ileostomy. Graft-versus-host disease manifests most commonly as skin lesions or mucosal lesions in the recipient s residual gastrointestinal tract both sites are best amenable for visual or endoscopic inspection and biopsies. 

Treatment of Acute Graft-Versus-Host Disease... 

Couriel D, Caldera H, Champlin R, Komanduri K. Acute graft-versus-host disease Pathophysiology, clinical manifestations, and management. Cancer 2004 101 1936-1946. 

Wysocki CA, Jiang Q, Panoskaltsis-Mortari A, et al. Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease. Blood 2005 106 3300-3307. 

Przepiorka D, Saliba R, Cleary K et al. Tacrolismus does not abrogate the increased risk of acute graft-versus-host disease after unrelated donor marrow transplantation with allelic mismatching at HLA-DRBl and HLA-DQBl. Biol. Blood Marrow Transplant 2000 6 190-197. 

G. Other applications Other possible uses of Orthoclone OKT3 are for prophylaxis and treatment of acute graft-versus-host disease (as an adjunct with allogeneic bone marrow transplantation) treatment of rejection after lung transplantation prophylaxis and treatment of rejection... 

Markus, P. M., Cai, X., Ming, W., Demetris, A. j., Fung, j. j., and Starzl, T. E. (1991). FK 506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats. Surgery 110, 357-364. 

Bone marrow transplantation Immune globulin (intravenous [IV])2 500 mg/kg IV on days 7 and 2 prior to transplantation and then once weekly through day 90 after transplantation. Prophylaxis to decrease the risk of infection, interstitial pneumonia, and acute graft-versus-host disease in... 

Le Blanc, K., Rasmusson, I., Sundberg, B., et al. (2004), Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells, Lancet, 1, 363(9419), 1439-1441. 

Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation Weisdorf, D., Hakke, R., Blazar, B., Miller, W., McGlave, P., Ramsay, N., Kersey, J., Filipovich, A. (1991). Transplantation, 51 (6) 1197-1203. 

Novel strategies for steroid-refractory acute graft-versus-host disease Bolanos-Meade, J., Vogelsang, G.B. (2005). Curr Opin Hematol, 12 (1) 40-44. 

Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneichematopoietic stem cell transplantation Ho,... 

Bordigoni P, Dimicoli S, Clement L, Baumann C. 2006. Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease. Br J Hematol. 135 382-385. 

Przepiorka D, Keman NA, Ipppoliti C, Papandopoulas EB, et al. 2000. Dachzumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for the treatment of acute graft-versus-host disease Blood. 2000 83-89. 

Ferrara JLM, Cooke KR, Pan L, Krenger W. 1996. The immunopathophysiology of acute graft-versus-host-disease. Stem cells. 14 473—489. 

Beckman RA, Siden R, Yanik GA, Levine JE. Continuous octreotide infusion for the treatment of secretory diarrhea caused by acute intestinal graft-versus-host disease in a child. J Pediatr Hematol Oncol 2000 22(4) 344—50. 

Zeiser R, Marks R, Bertz H, Finke J. Immunopatho-genesis of acute graft-versus-host disease implications for novel preventive and therapeutic strategies. Ann Hematol. 2004 83 551-565. 

Acute graft-versus-host disease Disease effect ws TFA Label-free Variable expression of S100 protein family members (S100A8, S100A9, and S100A7) was detected (79)... 

Ansetti, C., Hansen, J. A., Waldmann, T. A. el al. (1994). Treatment of acute graft-versus-host disease with humanized anti-Tac An antibody that binds to the inter-leukin-2 receptor. Blood84, 1320-1327. 

---